Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference15 articles.
1. Verstovsek S, Mesa RA, Gotlib JR, Levy RS, Gupta V, DiPersio JF et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol 2011; 29 (Suppl; abstr 6500): 419s.
2. Harrison CL, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol 2011; 29 (Suppl; abstr LBA6501): 419s.
3. Jakafi (Ruxolitinib) label
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf
.
4. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I. Blood 53rd ASH Annu Meet 2011; 118 (abstr no. 278): 128–129.
5. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A . JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25: 218–225.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献